#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-5	Brain	_
1-2	6-14	function	_
1-3	15-16	,	_
1-4	17-26	structure	_
1-5	27-30	and	_
1-6	31-38	genomic	_
1-7	39-43	data	_
1-8	44-47	are	_
1-9	48-54	linked	_
1-10	55-58	but	_
1-11	59-63	show	_
1-12	64-73	different	_
1-13	74-85	sensitivity	_
1-14	86-88	to	_
1-15	89-97	duration	_
1-16	98-100	of	_
1-17	101-108	illness	_
1-18	109-112	and	_
1-19	113-120	disease	_
1-20	121-126	stage	_
1-21	127-129	in	_
1-22	130-143	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-23	144-147	The	_
1-24	148-156	progress	_
1-25	157-159	of	_
1-26	160-173	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-27	174-176	at	_
1-28	177-184	various	_
1-29	185-191	stages	_
1-30	192-194	is	_
1-31	195-197	an	_
1-32	198-208	intriguing	_
1-33	209-217	question	_
1-34	218-219	,	_
1-35	220-225	which	_
1-36	226-229	has	_
1-37	230-234	been	_
1-38	235-243	explored	_
1-39	244-246	to	_
1-40	247-251	some	_
1-41	252-258	degree	_
1-42	259-264	using	_
1-43	265-280	single-modality	_
1-44	281-286	brain	_
1-45	287-294	imaging	_
1-46	295-299	data	_
1-47	300-301	,	_
1-48	302-305	e.g	_
1-49	306-307	.	_

2-1	308-312	gray	_
2-2	313-319	matter	_
2-3	320-321	(	_
2-4	322-324	GM	_
2-5	325-326	)	_
2-6	327-329	or	_
2-7	330-340	functional	_
2-8	341-353	connectivity	_
2-9	354-355	(	_
2-10	356-358	FC	_
2-11	359-360	)	_
2-12	361-362	.	_

3-1	363-370	However	_
3-2	371-373	it	_
3-3	374-381	remains	_
3-4	382-389	unclear	_
3-5	390-393	how	_
3-6	394-399	those	_
3-7	400-407	changes	_
3-8	408-412	from	_
3-9	413-422	different	_
3-10	423-433	modalities	_
3-11	434-437	are	_
3-12	438-448	correlated	_
3-13	449-453	with	_
3-14	454-458	each	_
3-15	459-464	other	_
3-16	465-468	and	_
3-17	469-471	if	_
3-18	472-475	the	_
3-19	476-487	sensitivity	_
3-20	488-490	to	_
3-21	491-499	duration	_
3-22	500-502	of	_
3-23	503-510	illness	_
3-24	511-514	and	_
3-25	515-522	disease	_
3-26	523-529	stages	_
3-27	530-536	across	_
3-28	537-547	modalities	_
3-29	548-550	is	_
3-30	551-560	different	_
3-31	561-562	.	_

4-1	563-565	In	_
4-2	566-570	this	_
4-3	571-575	work	_
4-4	576-577	,	_
4-5	578-580	we	_
4-6	581-588	jointly	_
4-7	589-597	analyzed	_
4-8	598-600	FC	_
4-9	601-602	,	_
4-10	603-605	GM	_
4-11	606-612	volume	_
4-12	613-616	and	_
4-13	617-623	single	_
4-14	624-634	nucleotide	_
4-15	635-648	polymorphisms	_
4-16	649-650	(	_
4-17	651-655	SNPs	_
4-18	656-657	)	_
4-19	658-662	data	_
4-20	663-665	of	_
4-21	666-669	159	_
4-22	670-681	individuals	_
4-23	682-691	including	_
4-24	692-699	healthy	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
4-25	700-708	controls	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
4-26	709-710	(	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
4-27	711-713	HC	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
4-28	714-715	)	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
4-29	716-717	,	_
4-30	718-728	drug-naïve	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
4-31	729-742	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
4-32	743-756	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
4-33	757-758	(	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
4-34	759-763	FESZ	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
4-35	764-765	)	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
4-36	766-769	and	_
4-37	770-777	chronic	http://maven.renci.org/NeuroBridge/neurobridge#ChronicSchizophrenia
4-38	778-791	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#ChronicSchizophrenia
4-39	792-800	patients	http://maven.renci.org/NeuroBridge/neurobridge#ChronicSchizophrenia
4-40	801-802	(	http://maven.renci.org/NeuroBridge/neurobridge#ChronicSchizophrenia
4-41	803-806	CSZ	http://maven.renci.org/NeuroBridge/neurobridge#ChronicSchizophrenia
4-42	807-808	)	http://maven.renci.org/NeuroBridge/neurobridge#ChronicSchizophrenia
4-43	809-810	,	_
4-44	811-817	aiming	_
4-45	818-820	to	_
4-46	821-829	evaluate	_
4-47	830-833	the	_
4-48	834-839	links	_
4-49	840-845	among	_
4-50	846-849	SNP	_
4-51	850-851	,	_
4-52	852-854	FC	_
4-53	855-858	and	_
4-54	859-861	GM	_
4-55	862-870	patterns	_
4-56	871-872	,	_
4-57	873-876	and	_
4-58	877-882	their	_
4-59	883-894	sensitivity	_
4-60	895-897	to	_
4-61	898-906	duration	_
4-62	907-909	of	_
4-63	910-917	illness	_
4-64	918-921	and	_
4-65	922-929	disease	_
4-66	930-936	stages	_
4-67	937-939	in	_
4-68	940-953	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-69	954-955	.	_

5-1	956-959	Our	_
5-2	960-967	results	_
5-3	968-977	suggested	_
5-4	978-979	:	_
5-5	980-981	1	_
5-6	982-983	)	_
5-7	984-988	both	_
5-8	989-991	GM	_
5-9	992-995	and	_
5-10	996-998	FC	_
5-11	999-1010	highlighted	_
5-12	1011-1022	impairments	_
5-13	1023-1025	in	_
5-14	1026-1037	hippocampal	_
5-15	1038-1039	,	_
5-16	1040-1048	temporal	_
5-17	1049-1054	gyrus	_
5-18	1055-1058	and	_
5-19	1059-1069	cerebellum	_
5-20	1070-1072	in	_
5-21	1073-1086	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-22	1087-1088	,	_
5-23	1089-1094	which	_
5-24	1095-1099	were	_
5-25	1100-1113	significantly	_
5-26	1114-1124	correlated	_
5-27	1125-1129	with	_
5-28	1130-1135	genes	_
5-29	1136-1140	like	_
5-30	1141-1146	SATB2	_
5-31	1147-1148	,	_
5-32	1149-1155	GABBR2	_
5-33	1156-1157	,	_
5-34	1158-1163	PDE4B	_
5-35	1164-1165	,	_
5-36	1166-1173	CACNA1C	_
5-37	1174-1177	etc	_
5-38	1178-1179	.	_

6-1	1180-1181	2	_
6-2	1182-1183	)	_
6-3	1184-1186	GM	_
6-4	1187-1190	and	_
6-5	1191-1193	FC	_
6-6	1194-1203	presented	_
6-7	1204-1213	gradually	_
6-8	1214-1222	decrease	_
6-9	1223-1228	trend	_
6-10	1229-1230	(	_
6-11	1231-1233	HC	_
6-12	1234-1235	>	_
6-13	1236-1240	FESZ	_
6-14	1241-1242	>	_
6-15	1243-1246	CSZ	_
6-16	1247-1248	)	_
6-17	1249-1250	,	_
6-18	1251-1256	while	_
6-19	1257-1260	SNP	_
6-20	1261-1270	indicated	_
6-21	1271-1272	a	_
6-22	1273-1284	non-gradual	_
6-23	1285-1294	variation	_
6-24	1295-1300	trend	_
6-25	1301-1305	with	_
6-26	1306-1320	un-significant	_
6-27	1321-1326	group	_
6-28	1327-1337	difference	_
6-29	1338-1346	observed	_
6-30	1347-1354	between	_
6-31	1355-1359	FESZ	_
6-32	1360-1363	and	_
6-33	1364-1367	CSZ	_
6-34	1368-1369	;	_
6-35	1370-1371	3	_
6-36	1372-1373	)	_
6-37	1374-1379	Group	_
6-38	1380-1390	difference	_
6-39	1391-1398	between	_
6-40	1399-1401	HC	_
6-41	1402-1405	and	_
6-42	1406-1410	FESZ	_
6-43	1411-1413	of	_
6-44	1414-1416	FC	_
6-45	1417-1420	was	_
6-46	1421-1425	more	_
6-47	1426-1436	remarkable	_
6-48	1437-1441	than	_
6-49	1442-1444	GM	_
6-50	1445-1446	,	_
6-51	1447-1450	and	_
6-52	1451-1453	FC	_
6-53	1454-1463	presented	_
6-54	1464-1465	a	_
6-55	1466-1474	stronger	_
6-56	1475-1483	negative	_
6-57	1484-1495	correlation	_
6-58	1496-1500	with	_
6-59	1501-1509	duration	_
6-60	1510-1512	of	_
6-61	1513-1520	illness	_
6-62	1521-1525	than	_
6-63	1526-1528	GM	_
6-64	1529-1530	(	_
6-65	1531-1532	p	_
6-66	1533-1534	=	_
6-67	1535-1541	0.0006	_
6-68	1542-1543	)	_
6-69	1544-1545	.	_

7-1	1546-1558	Collectively	_
7-2	1559-1560	,	_
7-3	1561-1566	these	_
7-4	1567-1574	results	_
7-5	1575-1584	highlight	_
7-6	1585-1588	the	_
7-7	1589-1596	benefit	_
7-8	1597-1599	of	_
7-9	1600-1610	leveraging	_
7-10	1611-1621	multimodal	_
7-11	1622-1626	data	_
7-12	1627-1630	and	_
7-13	1631-1638	provide	_
7-14	1639-1649	additional	_
7-15	1650-1655	clues	_
7-16	1656-1665	regarding	_
7-17	1666-1669	the	_
7-18	1670-1676	impact	_
7-19	1677-1679	of	_
7-20	1680-1686	mental	_
7-21	1687-1694	illness	_
7-22	1695-1697	at	_
7-23	1698-1705	various	_
7-24	1706-1713	disease	_
7-25	1714-1720	stages	_
7-26	1721-1722	.	_

8-1	1723-1733	Highlights	_
8-2	1734-1747	Investigation	_
8-3	1748-1750	of	_
8-4	1751-1757	linked	_
8-5	1758-1761	SNP	_
8-6	1762-1763	,	_
8-7	1764-1766	GM	_
8-8	1767-1770	and	_
8-9	1771-1773	FC	_
8-10	1774-1781	pattern	_
8-11	1782-1789	through	_
8-12	1790-1798	parallel	_
8-13	1799-1802	ICA	_
8-14	1803-1809	method	_
8-15	1810-1811	;	_
8-16	1812-1815	SNP	_
8-17	1816-1825	indicated	_
8-18	1826-1827	a	_
8-19	1828-1839	non-gradual	_
8-20	1840-1849	variation	_
8-21	1850-1855	trend	_
8-22	1856-1857	,	_
8-23	1858-1869	highlighted	_
8-24	1870-1875	genes	_
8-25	1876-1880	like	_
8-26	1881-1887	GABBR2	_
8-27	1888-1891	etc	_
8-28	1892-1893	.	_

9-1	1894-1895	;	_
9-2	1896-1898	GM	_
9-3	1899-1902	and	_
9-4	1903-1905	FC	_
9-5	1906-1915	exhibited	_
9-6	1916-1923	greater	_
9-7	1924-1932	deficits	_
9-8	1933-1935	at	_
9-9	1936-1940	late	_
9-10	1941-1948	disease	_
9-11	1949-1955	stages	_
9-12	1956-1957	(	_
9-13	1958-1960	HC	_
9-14	1961-1962	>	_
9-15	1963-1967	FESZ	_
9-16	1968-1969	>	_
9-17	1970-1973	CSZ	_
9-18	1974-1975	)	_
9-19	1976-1977	;	_
9-20	1978-1980	FC	_
9-21	1981-1990	presented	_
9-22	1991-1992	a	_
9-23	1993-2001	stronger	_
9-24	2002-2010	negative	_
9-25	2011-2022	correlation	_
9-26	2023-2027	with	_
9-27	2028-2036	duration	_
9-28	2037-2039	of	_
9-29	2040-2047	illness	_
9-30	2048-2052	than	_
9-31	2053-2055	GM	_
9-32	2056-2057	.	_

10-1	2058-2067	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-2	2068-2071	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-3	2072-2079	methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-4	2080-2092	Participants	_
10-5	2093-2096	159	_
10-6	2097-2105	subjects	_
10-7	2106-2110	were	_
10-8	2111-2120	recruited	_
10-9	2121-2125	from	_
10-10	2126-2130	Wuxi	_
10-11	2131-2137	Mental	_
10-12	2138-2144	Health	_
10-13	2145-2151	Center	_
10-14	2152-2153	,	_
10-15	2154-2164	consisting	_
10-16	2165-2167	of	_
10-17	2168-2180	eighty-seven	_
10-18	2181-2183	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
10-19	2184-2185	,	_
10-20	2186-2192	twenty	_
10-21	2193-2203	drug-naïve	http://maven.renci.org/NeuroBridge/neurobridge#DrugRelatedDisorder
10-22	2204-2209	FESZs	http://maven.renci.org/NeuroBridge/neurobridge#DrugRelatedDisorder
10-23	2210-2213	and	_
10-24	2214-2223	fifty-two	_
10-25	2224-2228	CSZs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
10-26	2229-2230	.	_

11-1	2231-2236	Table	_
11-2	2237-2238	1	_
11-3	2239-2248	describes	_
11-4	2249-2252	the	_
11-5	2253-2264	demographic	_
11-6	2265-2276	information	_
11-7	2277-2279	of	_
11-8	2280-2283	the	_
11-9	2284-2288	data	_
11-10	2289-2290	.	_

12-1	2291-2299	Patients	_
12-2	2300-2303	who	_
12-3	2304-2308	have	_
12-4	2309-2312	DOI	_
12-5	2313-2314	≤	_
12-6	2315-2316	2	_
12-7	2317-2322	years	_
12-8	2323-2327	were	_
12-9	2328-2336	definded	_
12-10	2337-2339	as	_
12-11	2340-2344	FESZ	_
12-12	2345-2353	patients	_
12-13	2354-2355	(	_
12-14	2356-2360	0.96	_
12-15	2361-2362	±	_
12-16	2363-2367	0.85	_
12-17	2368-2369	)	_
12-18	2370-2371	,	_
12-19	2372-2378	others	_
12-20	2379-2383	were	_
12-21	2384-2394	identified	_
12-22	2395-2397	as	_
12-23	2398-2405	chronic	_
12-24	2406-2414	patients	_
12-25	2415-2416	(	_
12-26	2417-2422	20.63	_
12-27	2423-2424	±	_
12-28	2425-2429	9.84	_
12-29	2430-2431	)	_
12-30	2432-2433	.	_

13-1	2434-2442	Subjects	_
13-2	2443-2447	were	_
13-3	2448-2456	excluded	_
13-4	2457-2459	if	_
13-5	2460-2464	they	_
13-6	2465-2468	had	_
13-7	2469-2472	any	_
13-8	2473-2480	current	_
13-9	2481-2483	or	_
13-10	2484-2488	past	_
13-11	2489-2501	neurological	_
13-12	2502-2509	illness	_
13-13	2510-2511	,	_
13-14	2512-2521	substance	_
13-15	2522-2527	abuse	_
13-16	2528-2530	or	_
13-17	2531-2535	head	_
13-18	2536-2542	injury	_
13-19	2543-2552	resulting	_
13-20	2553-2555	in	_
13-21	2556-2560	loss	_
13-22	2561-2563	of	_
13-23	2564-2577	consciousness	_
13-24	2578-2579	.	_

14-1	2580-2583	All	_
14-2	2584-2587	the	_
14-3	2588-2596	patients	_
14-4	2597-2601	were	_
14-5	2602-2611	diagnosed	_
14-6	2612-2621	according	_
14-7	2622-2624	to	_
14-8	2625-2628	the	_
14-9	2629-2635	DSM-IV	_
14-10	2636-2646	diagnostic	_
14-11	2647-2655	criteria	_
14-12	2656-2658	by	_
14-13	2659-2661	at	_
14-14	2662-2667	least	_
14-15	2668-2671	two	_
14-16	2672-2681	qualified	_
14-17	2682-2695	psychiatrists	_
14-18	2696-2697	.	_

15-1	2698-2702	Data	_
15-2	2703-2713	collection	_
15-3	2714-2717	All	_
15-4	2718-2726	subjects	_
15-5	2727-2731	were	_
15-6	2732-2739	scanned	_
15-7	2740-2742	by	_
15-8	2743-2753	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
15-9	2754-2757	MRI	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
15-10	2758-2761	and	_
15-11	2762-2775	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
15-12	2776-2786	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
15-13	2787-2790	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
15-14	2791-2793	on	_
15-15	2794-2795	a	_
15-16	2796-2805	3.0-Tesla	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
15-17	2806-2814	Magnetom	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
15-18	2815-2818	TIM	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
15-19	2819-2823	Trio	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
15-20	2824-2825	(	_
15-21	2826-2833	Siemens	_
15-22	2834-2841	Medical	_
15-23	2842-2848	System	_
15-24	2849-2850	)	_
15-25	2851-2853	at	_
15-26	2854-2857	the	_
15-27	2858-2868	Department	_
15-28	2869-2871	of	_
15-29	2872-2879	Medical	_
15-30	2880-2887	Imaging	_
15-31	2888-2889	,	_
15-32	2890-2894	Wuxi	_
15-33	2895-2901	People	_
15-34	2902-2904	's	_
15-35	2905-2913	Hospital	_
15-36	2914-2915	,	_
15-37	2916-2923	Nanjing	_
15-38	2924-2931	Medical	_
15-39	2932-2942	University	_
15-40	2943-2944	.	_

16-1	2945-2949	Foam	_
16-2	2950-2954	pads	_
16-3	2955-2959	were	_
16-4	2960-2964	used	_
16-5	2965-2967	to	_
16-6	2968-2974	reduce	_
16-7	2975-2979	head	_
16-8	2980-2986	motion	_
16-9	2987-2990	and	_
16-10	2991-2998	scanner	_
16-11	2999-3004	noise	_
16-12	3005-3006	.	_

17-1	3007-3012	Prior	_
17-2	3013-3015	to	_
17-3	3016-3019	the	_
17-4	3020-3024	scan	_
17-5	3025-3026	,	_
17-6	3027-3030	the	_
17-7	3031-3039	subjects	_
17-8	3040-3044	were	_
17-9	3045-3055	instructed	_
17-10	3056-3058	to	_
17-11	3059-3063	keep	_
17-12	3064-3069	their	_
17-13	3070-3074	eyes	_
17-14	3075-3081	closed	_
17-15	3082-3083	,	_
17-16	3084-3089	relax	_
17-17	3090-3093	but	_
17-18	3094-3097	not	_
17-19	3098-3102	fall	_
17-20	3103-3109	asleep	_
17-21	3110-3111	,	_
17-22	3112-3115	and	_
17-23	3116-3120	move	_
17-24	3121-3123	as	_
17-25	3124-3130	little	_
17-26	3131-3133	as	_
17-27	3134-3142	possible	_
17-28	3143-3149	during	_
17-29	3150-3154	data	_
17-30	3155-3166	acquisition	_
17-31	3167-3168	.	_

18-1	3169-3173	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
18-2	3174-3175	:	_
18-3	3176-3189	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
18-4	3190-3195	scans	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
18-5	3196-3200	were	_
18-6	3201-3209	acquired	_
18-7	3210-3215	using	_
18-8	3216-3217	a	_
18-9	3218-3229	single-shot	_
18-10	3230-3243	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
18-11	3244-3263	echo-planar-imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
18-12	3264-3272	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
18-13	3273-3275	as	_
18-14	3276-3280	with	_
18-15	3281-3284	the	_
18-16	3285-3294	following	_
18-17	3295-3305	parameters	_
18-18	3306-3307	:	_
18-19	3308-3310	TR	_
18-20	3311-3312	=	_
18-21	3313-3317	2000	_
18-22	3318-3320	ms	_
18-23	3321-3322	,	_
18-24	3323-3325	TE	_
18-25	3326-3327	=	_
18-26	3328-3330	30	_
18-27	3331-3333	ms	_
18-28	3334-3335	,	_
18-29	3336-3340	flip	_
18-30	3341-3346	angle	_
18-31	3347-3348	=	_
18-32	3349-3352	90°	_
18-33	3353-3354	,	_
18-34	3355-3361	matrix	_
18-35	3362-3366	size	_
18-36	3367-3368	=	_
18-37	3369-3371	64	_
18-38	3372-3373	×	_
18-39	3374-3376	64	_
18-40	3377-3378	,	_
18-41	3379-3382	FOV	_
18-42	3383-3384	=	_
18-43	3385-3388	220	_
18-44	3389-3390	×	_
18-45	3391-3394	220	_
18-46	3395-3398	mm2	_
18-47	3399-3400	,	_
18-48	3401-3403	33	_
18-49	3404-3409	axial	_
18-50	3410-3416	slices	_
18-51	3417-3418	,	_
18-52	3419-3424	slice	_
18-53	3425-3434	thickness	_
18-54	3435-3436	=	_
18-55	3437-3438	4	_
18-56	3439-3441	mm	_
18-57	3442-3443	,	_
18-58	3444-3455	acquisition	_
18-59	3456-3461	voxel	_
18-60	3462-3466	size	_
18-61	3467-3468	=	_
18-62	3469-3472	3.4	_
18-63	3473-3474	×	_
18-64	3475-3478	3.4	_
18-65	3479-3480	×	_
18-66	3481-3482	4	_
18-67	3483-3486	mm3	_
18-68	3487-3488	,	_
18-69	3489-3498	resulting	_
18-70	3499-3501	in	_
18-71	3502-3505	240	_
18-72	3506-3513	volumes	_
18-73	3514-3515	.	_

19-1	3516-3520	sMRI	http://maven.renci.org/NeuroBridge/neurobridge#Thing
19-2	3521-3522	:	_
19-3	3523-3540	Three-dimensional	http://maven.renci.org/NeuroBridge/neurobridge#ThreeLeadElectrocardiograph
19-4	3541-3552	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
19-5	3553-3559	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
19-6	3560-3564	were	_
19-7	3565-3573	acquired	_
19-8	3574-3576	by	_
19-9	3577-3586	employing	_
19-10	3587-3588	a	_
19-11	3589-3598	3D-MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
19-12	3599-3607	sequence	_
19-13	3608-3610	as	_
19-14	3611-3615	with	_
19-15	3616-3619	the	_
19-16	3620-3629	following	_
19-17	3630-3640	parameters	_
19-18	3641-3642	:	_
19-19	3643-3647	time	_
19-20	3648-3658	repetition	_
19-21	3659-3660	(	_
19-22	3661-3663	TR	_
19-23	3664-3665	)	_
19-24	3666-3667	=	_
19-25	3668-3672	2530	_
19-26	3673-3675	ms	_
19-27	3676-3677	,	_
19-28	3678-3682	time	_
19-29	3683-3687	echo	_
19-30	3688-3689	(	_
19-31	3690-3692	TE	_
19-32	3693-3694	)	_
19-33	3695-3696	=	_
19-34	3697-3701	3.44	_
19-35	3702-3704	ms	_
19-36	3705-3706	,	_
19-37	3707-3711	flip	_
19-38	3712-3717	angle	_
19-39	3718-3719	=	_
19-40	3720-3722	7°	_
19-41	3723-3724	,	_
19-42	3725-3731	matrix	_
19-43	3732-3736	size	_
19-44	3737-3738	=	_
19-45	3739-3742	256	_
19-46	3743-3744	×	_
19-47	3745-3748	256	_
19-48	3749-3750	,	_
19-49	3751-3756	field	_
19-50	3757-3759	of	_
19-51	3760-3764	view	_
19-52	3765-3766	(	_
19-53	3767-3770	FOV	_
19-54	3771-3772	)	_
19-55	3773-3774	=	_
19-56	3775-3778	256	_
19-57	3779-3780	×	_
19-58	3781-3784	256	_
19-59	3785-3788	mm2	_
19-60	3789-3790	,	_
19-61	3791-3794	192	_
19-62	3795-3803	sagittal	_
19-63	3804-3810	slices	_
19-64	3811-3812	,	_
19-65	3813-3818	slice	_
19-66	3819-3828	thickness	_
19-67	3829-3830	=	_
19-68	3831-3832	1	_
19-69	3833-3835	mm	_
19-70	3836-3837	,	_
19-71	3838-3849	acquisition	_
19-72	3850-3855	voxel	_
19-73	3856-3860	size	_
19-74	3861-3862	=	_
19-75	3863-3864	1	_
19-76	3865-3866	×	_
19-77	3867-3868	1	_
19-78	3869-3870	×	_
19-79	3871-3872	1	_
19-80	3873-3876	mm3	_
19-81	3877-3878	,	_
19-82	3879-3884	total	_
19-83	3885-3896	acquisition	_
19-84	3897-3901	time	_
19-85	3902-3903	=	_
19-86	3904-3907	649	_
19-87	3908-3910	s.	_
19-88	3911-3914	All	_
19-89	3915-3927	participants	_
19-90	3928-3936	provided	_
19-91	3937-3942	blood	_
19-92	3943-3950	samples	_
19-93	3951-3954	for	_
19-94	3955-3962	genetic	_
19-95	3963-3971	analysis	_
19-96	3972-3973	.	_

20-1	3974-3981	Genomic	_
20-2	3982-3998	deoxyribonucleic	_
20-3	3999-4003	acid	_
20-4	4004-4005	(	_
20-5	4006-4009	DNA	_
20-6	4010-4011	)	_
20-7	4012-4015	was	_
20-8	4016-4025	extracted	_
20-9	4026-4035	according	_
20-10	4036-4038	to	_
20-11	4039-4042	the	_
20-12	4043-4051	standard	_
20-13	4052-4060	protocol	_
20-14	4061-4063	by	_
20-15	4064-4072	protease	_
20-16	4073-4074	K	_
20-17	4075-4084	digestion	_
20-18	4085-4086	,	_
20-19	4087-4104	phenol-chloroform	_
20-20	4105-4115	extraction	_
20-21	4116-4119	and	_
20-22	4120-4127	ethanol	_
20-23	4128-4141	precipitation	_
20-24	4142-4143	.	_

21-1	4144-4154	Afterwards	_
21-2	4155-4156	,	_
21-3	4157-4169	whole-genome	_
21-4	4170-4180	genotyping	_
21-5	4181-4184	was	_
21-6	4185-4194	conducted	_
21-7	4195-4197	on	_
21-8	4198-4205	571,054	_
21-9	4206-4210	loci	_
21-10	4211-4216	using	_
21-11	4217-4225	Illumina	_
21-12	4226-4231	human	_
21-13	4232-4245	PsychArray-24	_
21-14	4246-4247	.	_

22-1	4248-4252	Data	_
22-2	4253-4266	preprocessing	_
22-3	4267-4270	The	_
22-4	4271-4281	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
22-5	4282-4285	MRI	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
22-6	4286-4290	data	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
22-7	4291-4294	and	_
22-8	4295-4305	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
22-9	4306-4309	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
22-10	4310-4314	data	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
22-11	4315-4319	were	_
22-12	4320-4332	preprocessed	_
22-13	4333-4338	using	_
22-14	4339-4342	the	_
22-15	4343-4347	SPM8	_
22-16	4348-4349	(	_
22-17	4350-4389	www.fil.ion.ucl.ac.uk/spm/software/spm8	_
22-18	4390-4391	)	_
22-19	4392-4397	voxel	_
22-20	4398-4403	based	_
22-21	4404-4415	morphometry	_
22-22	4416-4422	module	_
22-23	4423-4426	and	_
22-24	4427-4430	the	_
22-25	4431-4436	Brant	_
22-26	4437-4445	software	_
22-27	4446-4447	(	_
22-28	4448-4452	http	_
22-29	4453-4454	:	_
22-30	4455-4489	//brant.brainnetome.org/en/latest/	_
22-31	4490-4491	,	_
22-32	4492-4493	)	_
22-33	4494-4495	,	_
22-34	4496-4508	respectively	_
22-35	4509-4510	(	_
22-36	4511-4514	see	_
22-37	4515-4528	supplementary	_
22-38	4529-4533	file	_
22-39	4534-4537	for	_
22-40	4538-4542	more	_
22-41	4543-4550	details	_
22-42	4551-4552	)	_
22-43	4553-4554	.	_

23-1	4555-4556	A	_
23-2	4557-4561	mask	_
23-3	4562-4565	for	_
23-4	4566-4569	the	_
23-5	4570-4582	preprocessed	_
23-6	4583-4593	structural	_
23-7	4594-4598	data	_
23-8	4599-4602	was	_
23-9	4603-4607	then	_
23-10	4608-4617	generated	_
23-11	4618-4620	to	_
23-12	4621-4628	include	_
23-13	4629-4635	voxels	_
23-14	4636-4640	with	_
23-15	4641-4642	a	_
23-16	4643-4647	mean	_
23-17	4648-4653	value	_
23-18	4654-4660	larger	_
23-19	4661-4665	than	_
23-20	4666-4669	0.2	_
23-21	4670-4676	across	_
23-22	4677-4680	all	_
23-23	4681-4684	the	_
23-24	4685-4693	subjects	_
23-25	4694-4695	.	_

24-1	4696-4701	Based	_
24-2	4702-4704	on	_
24-3	4705-4708	the	_
24-4	4709-4712	116	_
24-5	4713-4714	×	_
24-6	4715-4718	116	_
24-7	4719-4728	automatic	_
24-8	4729-4739	anatomical	_
24-9	4740-4749	labelling	_
24-10	4750-4751	(	_
24-11	4752-4755	AAL	_
24-12	4756-4757	)	_
24-13	4758-4763	atlas	_
24-14	4764-4765	,	_
24-15	4766-4768	FC	_
24-16	4769-4776	network	_
24-17	4777-4780	was	_
24-18	4781-4792	constructed	_
24-19	4793-4797	upon	_
24-20	4798-4807	computing	_
24-21	4808-4815	pearson	_
24-22	4816-4827	correlation	_
24-23	4828-4830	of	_
24-24	4831-4839	averaged	_
24-25	4840-4844	BOLD	_
24-26	4845-4852	signals	_
24-27	4853-4860	between	_
24-28	4861-4864	all	_
24-29	4865-4870	pairs	_
24-30	4871-4873	of	_
24-31	4874-4881	regions	_
24-32	4882-4883	,	_
24-33	4884-4893	resulting	_
24-34	4894-4896	in	_
24-35	4897-4901	6786	_
24-36	4902-4907	edges	_
24-37	4908-4909	.	_

25-1	4910-4913	The	_
25-2	4914-4921	genetic	_
25-3	4922-4926	data	_
25-4	4927-4931	were	_
25-5	4932-4944	preprocessed	_
25-6	4945-4950	using	_
25-7	4951-4956	PLINK	_
25-8	4957-4966	following	_
25-9	4967-4970	the	_
25-10	4971-4978	quality	_
25-11	4979-4986	control	_
25-12	4987-4997	procedures	_
25-13	4998-5000	in	_
25-14	5001-5004	and	_
25-15	5005-5012	further	_
25-16	5013-5022	overlaped	_
25-17	5023-5027	with	_
25-18	5028-5031	PGC	_
25-19	5032-5034	's	_
25-20	5035-5039	SCZ2	_
25-21	5040-5048	database	_
25-22	5049-5050	(	_
25-23	5051-5052	p	_
25-24	5053-5054	<	_
25-25	5055-5059	0.01	_
25-26	5060-5061	)	_
25-27	5062-5063	,	_
25-28	5064-5073	resulting	_
25-29	5074-5076	in	_
25-30	5077-5081	4937	_
25-31	5082-5086	SNPs	_
25-32	5087-5088	(	_
25-33	5089-5092	see	_
25-34	5093-5106	supplementary	_
25-35	5107-5111	file	_
25-36	5112-5113	)	_
25-37	5114-5115	.	_

26-1	5116-5124	Discrete	_
26-2	5125-5132	numbers	_
26-3	5133-5137	were	_
26-4	5138-5146	assigned	_
26-5	5147-5149	to	_
26-6	5150-5153	the	_
26-7	5154-5165	categorical	_
26-8	5166-5175	genotypes	_
26-9	5176-5177	:	_
26-10	5178-5179	0	_
26-11	5180-5183	for	_
26-12	5184-5186	no	_
26-13	5187-5192	minor	_
26-14	5193-5199	allele	_
26-15	5200-5201	,	_
26-16	5202-5203	1	_
26-17	5204-5207	for	_
26-18	5208-5211	one	_
26-19	5212-5217	minor	_
26-20	5218-5224	allele	_
26-21	5225-5226	,	_
26-22	5227-5230	and	_
26-23	5231-5232	2	_
26-24	5233-5236	for	_
26-25	5237-5240	two	_
26-26	5241-5246	minor	_
26-27	5247-5254	alleles	_
26-28	5255-5256	.	_

27-1	5257-5268	Accordingly	_
27-2	5269-5270	,	_
27-3	5271-5274	the	_
27-4	5275-5280	three	_
27-5	5281-5288	feature	_
27-6	5289-5297	matrices	_
27-7	5298-5306	included	_
27-8	5307-5308	:	_
27-9	5309-5311	FC	_
27-10	5312-5313	(	_
27-11	5314-5322	subjects	_
27-12	5323-5325	by	_
27-13	5326-5332	voxels	_
27-14	5333-5334	:	_
27-15	5335-5338	159	_
27-16	5339-5340	×	_
27-17	5341-5345	6786	_
27-18	5346-5347	)	_
27-19	5348-5349	,	_
27-20	5350-5352	GM	_
27-21	5353-5354	(	_
27-22	5355-5363	subjects	_
27-23	5364-5366	by	_
27-24	5367-5373	voxels	_
27-25	5374-5375	:	_
27-26	5376-5379	159	_
27-27	5380-5381	×	_
27-28	5382-5388	77,122	_
27-29	5389-5390	)	_
27-30	5391-5394	and	_
27-31	5395-5399	SNPs	_
27-32	5400-5401	(	_
27-33	5402-5410	subjects	_
27-34	5411-5413	by	_
27-35	5414-5425	alleles:159	_
27-36	5426-5427	×	_
27-37	5428-5432	4937	_
27-38	5433-5434	)	_
27-39	5435-5436	.	_

28-1	5437-5440	The	_
28-2	5441-5448	feature	_
28-3	5449-5457	matrices	_
28-4	5458-5462	were	_
28-5	5463-5467	then	_
28-6	5468-5478	normalized	_
28-7	5479-5481	to	_
28-8	5482-5488	ensure	_
28-9	5489-5493	that	_
28-10	5494-5497	all	_
28-11	5498-5508	modalities	_
28-12	5509-5512	had	_
28-13	5513-5516	the	_
28-14	5517-5521	same	_
28-15	5522-5529	average	_
28-16	5530-5544	sum-of-squares	_
28-17	5545-5546	(	_
28-18	5547-5555	computed	_
28-19	5556-5562	across	_
28-20	5563-5566	all	_
28-21	5567-5575	subjects	_
28-22	5576-5579	and	_
28-23	5580-5583	all	_
28-24	5584-5595	voxels/SNPs	_
28-25	5596-5599	for	_
28-26	5600-5604	each	_
28-27	5605-5613	modality	_
28-28	5614-5615	)	_
28-29	5616-5617	.	_

29-1	5618-5628	Medication	_
29-2	5629-5640	information	_
29-3	5641-5642	(	_
29-4	5643-5657	chlorpromazine	_
29-5	5658-5668	equivalent	_
29-6	5669-5670	)	_
29-7	5671-5674	was	_
29-8	5675-5684	regressed	_
29-9	5685-5688	out	_
29-10	5689-5692	for	_
29-11	5693-5696	the	_
29-12	5697-5704	chronic	_
29-13	5705-5713	patients	_
29-14	5714-5719	prior	_
29-15	5720-5722	to	_
29-16	5723-5733	additional	_
29-17	5734-5742	analyses	_
29-18	5743-5744	.	_

30-1	5745-5749	Data	_
30-2	5750-5758	analysis	_
30-3	5759-5768	Three-way	_
30-4	5769-5777	para-ICA	_
30-5	5778-5780	We	_
30-6	5781-5788	firstly	_
30-7	5789-5796	applied	_
30-8	5797-5806	three-way	_
30-9	5807-5815	para-ICA	_
30-10	5816-5818	to	_
30-11	5819-5827	identify	_
30-12	5828-5829	a	_
30-13	5830-5836	linked	_
30-14	5837-5846	SNP-FC-GM	_
30-15	5847-5854	pattern	_
30-16	5855-5857	as	_
30-17	5858-5863	shown	_
30-18	5864-5866	in	_
30-19	5867-5870	Fig	_
30-20	5871-5872	.	_

31-1	5873-5874	1	_
31-2	5875-5876	.	_

32-1	5877-5886	Three-way	_
32-2	5887-5895	para-ICA	_
32-3	5896-5898	is	_
32-4	5899-5900	a	_
32-5	5901-5913	multivariate	_
32-6	5914-5925	association	_
32-7	5926-5934	analysis	_
32-8	5935-5941	method	_
32-9	5942-5946	that	_
32-10	5947-5956	estimates	_
32-11	5957-5966	maximally	_
32-12	5967-5978	independent	_
32-13	5979-5989	components	_
32-14	5990-5996	within	_
32-15	5997-6001	each	_
32-16	6002-6010	modality	_
32-17	6011-6016	using	_
32-18	6017-6024	Infomax	_
32-19	6025-6028	ICA	_
32-20	6029-6039	separately	_
32-21	6040-6043	and	_
32-22	6044-6053	maximizes	_
32-23	6054-6057	the	_
32-24	6058-6061	sum	_
32-25	6062-6064	of	_
32-26	6065-6074	pair-wise	_
32-27	6075-6087	correlations	_
32-28	6088-6095	between	_
32-29	6096-6106	modalities	_
32-30	6107-6108	(	_
32-31	6109-6115	Method	_
32-32	6116-6123	details	_
32-33	6124-6127	are	_
32-34	6128-6136	provided	_
32-35	6137-6139	in	_
32-36	6140-6143	the	_
32-37	6144-6157	supplementary	_
32-38	6158-6162	file	_
32-39	6163-6164	)	_
32-40	6165-6166	.	_

33-1	6167-6170	The	_
33-2	6171-6175	code	_
33-3	6176-6178	is	_
33-4	6179-6183	open	_
33-5	6184-6191	through	_
33-6	6192-6195	the	_
33-7	6196-6202	Fusion	_
33-8	6203-6206	ICA	_
33-9	6207-6214	Toolbox	_
33-10	6215-6216	(	_
33-11	6217-6220	FIT	_
33-12	6221-6222	,	_
33-13	6223-6227	http	_
33-14	6228-6229	:	_
33-15	6230-6259	//mialab.mrn.org/software/fit	_
33-16	6260-6261	)	_
33-17	6262-6263	.	_

34-1	6264-6267	The	_
34-2	6268-6274	number	_
34-3	6275-6277	of	_
34-4	6278-6288	components	_
34-5	6289-6292	was	_
34-6	6293-6301	measured	_
34-7	6302-6304	to	_
34-8	6305-6307	be	_
34-9	6308-6310	14	_
34-10	6311-6314	for	_
34-11	6315-6317	FC	_
34-12	6318-6321	and	_
34-13	6322-6324	GM	_
34-14	6325-6336	modalitites	_
34-15	6337-6344	through	_
34-16	6345-6346	a	_
34-17	6347-6355	modified	_
34-18	6356-6363	minimum	_
34-19	6364-6375	description	_
34-20	6376-6382	length	_
34-21	6383-6384	(	_
34-22	6385-6388	MDL	_
34-23	6389-6390	)	_
34-24	6391-6400	criterion	_
34-25	6401-6402	,	_
34-26	6403-6405	an	_
34-27	6406-6415	efficient	_
34-28	6416-6422	method	_
34-29	6423-6425	as	_
34-30	6426-6435	discussed	_
34-31	6436-6438	in	_
34-32	6439-6447	previous	_
34-33	6448-6451	ICA	_
34-34	6452-6462	associated	_
34-35	6463-6470	studies	_
34-36	6471-6472	.	_

35-1	6473-6474	A	_
35-2	6475-6492	consistency-based	_
35-3	6493-6499	method	_
35-4	6500-6503	was	_
35-5	6504-6508	used	_
35-6	6509-6511	to	_
35-7	6512-6520	identify	_
35-8	6521-6527	number	_
35-9	6528-6530	of	_
35-10	6531-6541	components	_
35-11	6542-6545	for	_
35-12	6546-6549	the	_
35-13	6550-6553	SNP	_
35-14	6554-6562	modality	_
35-15	6563-6564	,	_
35-16	6565-6570	which	_
35-17	6571-6574	ran	_
35-18	6575-6578	ICA	_
35-19	6579-6593	decompositions	_
35-20	6594-6600	across	_
35-21	6601-6602	a	_
35-22	6603-6608	range	_
35-23	6609-6611	of	_
35-24	6612-6619	numbers	_
35-25	6620-6622	of	_
35-26	6623-6633	components	_
35-27	6634-6637	and	_
35-28	6638-6648	determined	_
35-29	6649-6652	the	_
35-30	6653-6663	comoponent	_
35-31	6664-6670	number	_
35-32	6671-6675	with	_
35-33	6676-6679	the	_
35-34	6680-6684	most	_
35-35	6685-6693	reliable	_
35-36	6694-6701	results	_
35-37	6702-6703	(	_
35-38	6704-6706	in	_
35-39	6707-6710	our	_
35-40	6711-6715	case	_
35-41	6716-6719	the	_
35-42	6720-6725	final	_
35-43	6726-6731	model	_
35-44	6732-6737	order	_
35-45	6738-6741	was	_
35-46	6742-6751	estimated	_
35-47	6752-6754	to	_
35-48	6755-6757	be	_
35-49	6758-6759	6	_
35-50	6760-6761	)	_
35-51	6762-6763	.	_

36-1	6764-6775	Correlation	_
36-2	6776-6779	and	_
36-3	6780-6785	group	_
36-4	6786-6796	difference	_
36-5	6797-6805	analysis	_
36-6	6806-6811	Cross	_
36-7	6812-6824	correlations	_
36-8	6825-6830	among	_
36-9	6831-6834	the	_
36-10	6835-6842	loading	_
36-11	6843-6853	parameters	_
36-12	6854-6856	of	_
36-13	6857-6860	the	_
36-14	6861-6866	three	_
36-15	6867-6877	modalities	_
36-16	6878-6882	were	_
36-17	6883-6891	assessed	_
36-18	6892-6893	,	_
36-19	6894-6897	and	_
36-20	6898-6901	the	_
36-21	6902-6913	significant	_
36-22	6914-6920	levels	_
36-23	6921-6925	were	_
36-24	6926-6934	adjusted	_
36-25	6935-6940	using	_
36-26	6941-6951	Bonferroni	_
36-27	6952-6962	correction	_
36-28	6963-6966	for	_
36-29	6967-6975	multiple	_
36-30	6976-6986	comparison	_
36-31	6987-6988	.	_

37-1	6989-6991	To	_
37-2	6992-6999	measure	_
37-3	7000-7003	the	_
37-4	7004-7015	consistency	_
37-5	7016-7018	of	_
37-6	7019-7022	the	_
37-7	7023-7033	identified	_
37-8	7034-7039	joint	_
37-9	7040-7047	pattern	_
37-10	7048-7054	across	_
37-11	7055-7067	participants	_
37-12	7068-7069	,	_
37-13	7070-7072	we	_
37-14	7073-7080	applied	_
37-15	7081-7082	a	_
37-16	7083-7091	ten-fold	_
37-17	7092-7097	cross	_
37-18	7098-7108	validation	_
37-19	7109-7115	method	_
37-20	7116-7118	to	_
37-21	7119-7128	replicate	_
37-22	7129-7132	the	_
37-23	7133-7145	associations	_
37-24	7146-7147	.	_

38-1	7148-7156	Moreover	_
38-2	7157-7158	,	_
38-3	7159-7161	in	_
38-4	7162-7167	order	_
38-5	7168-7170	to	_
38-6	7171-7179	evaluate	_
38-7	7180-7183	the	_
38-8	7184-7193	stability	_
38-9	7194-7196	of	_
38-10	7197-7200	the	_
38-11	7201-7207	linked	_
38-12	7208-7217	SNP-FC-GM	_
38-13	7218-7225	pattern	_
38-14	7226-7227	,	_
38-15	7228-7230	we	_
38-16	7231-7240	conducted	_
38-17	7241-7245	1000	_
38-18	7246-7257	permutation	_
38-19	7258-7263	tests	_
38-20	7264-7266	to	_
38-21	7267-7278	investigate	_
38-22	7279-7282	the	_
38-23	7283-7294	possibility	_
38-24	7295-7297	of	_
38-25	7298-7309	overfitting	_
38-26	7310-7311	.	_

39-1	7312-7324	Particularly	_
39-2	7325-7326	,	_
39-3	7327-7329	we	_
39-4	7330-7338	randomly	_
39-5	7339-7347	permuted	_
39-6	7348-7356	subjects	_
39-7	7357-7359	of	_
39-8	7360-7363	all	_
39-9	7364-7367	the	_
39-10	7368-7373	three	_
39-11	7374-7384	modalities	_
39-12	7385-7388	and	_
39-13	7389-7392	ran	_
39-14	7393-7402	three-way	_
39-15	7403-7411	para-ICA	_
39-16	7412-7417	again	_
39-17	7418-7420	on	_
39-18	7421-7424	the	_
39-19	7425-7433	permuted	_
39-20	7434-7442	subjects	_
39-21	7443-7444	.	_

40-1	7445-7449	Then	_
40-2	7450-7452	we	_
40-3	7453-7462	extracted	_
40-4	7463-7466	the	_
40-5	7467-7470	top	_
40-6	7471-7481	correlated	_
40-7	7482-7491	SNP-FC-GM	_
40-8	7492-7496	pair	_
40-9	7497-7499	in	_
40-10	7500-7504	each	_
40-11	7505-7507	of	_
40-12	7508-7511	the	_
40-13	7512-7516	1000	_
40-14	7517-7528	permutation	_
40-15	7529-7534	tests	_
40-16	7535-7538	and	_
40-17	7539-7549	calculated	_
40-18	7550-7553	the	_
40-19	7554-7558	tail	_
40-20	7559-7570	probability	_
40-21	7571-7573	to	_
40-22	7574-7582	evaluate	_
40-23	7583-7586	the	_
40-24	7587-7599	significance	_
40-25	7600-7605	level	_
40-26	7606-7608	of	_
40-27	7609-7612	the	_
40-28	7613-7623	identified	_
40-29	7624-7633	SNP-FC-GM	_
40-30	7634-7645	association	_
40-31	7646-7647	.	_

41-1	7648-7655	Finally	_
41-2	7656-7657	,	_
41-3	7658-7661	the	_
41-4	7662-7668	sptial	_
41-5	7669-7673	maps	_
41-6	7674-7676	of	_
41-7	7677-7680	the	_
41-8	7681-7691	SNP-FC-SNP	_
41-9	7692-7699	pattern	_
41-10	7700-7704	were	_
41-11	7705-7716	transformed	_
41-12	7717-7719	to	_
41-13	7720-7721	Z	_
41-14	7722-7728	scores	_
41-15	7729-7732	and	_
41-16	7733-7736	the	_
41-17	7737-7740	top	_
41-18	7741-7753	contributing	_
41-19	7754-7759	brain	_
41-20	7760-7767	regions	_
41-21	7768-7769	,	_
41-22	7770-7772	FC	_
41-23	7773-7776	and	_
41-24	7777-7781	SNPs	_
41-25	7782-7786	were	_
41-26	7787-7795	selected	_
41-27	7796-7799	and	_
41-28	7800-7807	plotted	_
41-29	7808-7809	.	_

42-1	7810-7821	Sensitivity	_
42-2	7822-7824	to	_
42-3	7825-7832	disease	_
42-4	7833-7839	stages	_
42-5	7840-7843	and	_
42-6	7844-7847	DOI	_
42-7	7848-7850	To	_
42-8	7851-7862	investigate	_
42-9	7863-7866	the	_
42-10	7867-7876	different	_
42-11	7877-7890	sensitivities	_
42-12	7891-7893	to	_
42-13	7894-7900	diease	_
42-14	7901-7907	stages	_
42-15	7908-7911	and	_
42-16	7912-7915	DOI	_
42-17	7916-7917	,	_
42-18	7918-7920	we	_
42-19	7921-7928	applied	_
42-20	7929-7937	analysis	_
42-21	7938-7940	of	_
42-22	7941-7949	variance	_
42-23	7950-7951	(	_
42-24	7952-7957	ANOVA	_
42-25	7958-7959	)	_
42-26	7960-7968	analysis	_
42-27	7969-7972	and	_
42-28	7973-7976	two	_
42-29	7977-7983	sample	_
42-30	7984-7990	t-test	_
42-31	7991-7993	to	_
42-32	7994-8001	measure	_
42-33	8002-8005	the	_
42-34	8006-8011	group	_
42-35	8012-8022	difference	_
42-36	8023-8029	across	_
42-37	8030-8039	different	_
42-38	8040-8047	disease	_
42-39	8048-8054	stages	_
42-40	8055-8061	within	_
42-41	8062-8066	each	_
42-42	8067-8075	modality	_
42-43	8076-8079	for	_
42-44	8080-8083	the	_
42-45	8084-8090	linked	_
42-46	8091-8100	SNP-FC-GM	_
42-47	8101-8108	pattern	_
42-48	8109-8110	(	_
42-49	8111-8114	Fig	_
42-50	8115-8116	.	_

43-1	8117-8118	1	_
43-2	8119-8120	)	_
43-3	8121-8122	.	_

44-1	8123-8127	Then	_
44-2	8128-8130	we	_
44-3	8131-8141	calculated	_
44-4	8142-8145	the	_
44-5	8146-8158	relationship	_
44-6	8159-8166	between	_
44-7	8167-8170	the	_
44-8	8171-8181	identified	_
44-9	8182-8189	imaging	_
44-10	8190-8200	modalities	_
44-11	8201-8204	and	_
44-12	8205-8208	DOI	_
44-13	8209-8210	,	_
44-14	8211-8214	and	_
44-15	8215-8219	used	_
44-16	8220-8221	Z	_
44-17	8222-8227	value	_
44-18	8228-8230	to	_
44-19	8231-8238	compare	_
44-20	8239-8242	the	_
44-21	8243-8253	difference	_
44-22	8254-8261	between	_
44-23	8262-8268	slopes	_
44-24	8269-8271	of	_
44-25	8272-8275	the	_
44-26	8276-8279	two	_
44-27	8280-8290	modalities	_
44-28	8291-8292	.	_

45-1	8293-8305	Specifically	_
45-2	8306-8307	,	_
45-3	8308-8310	we	_
45-4	8311-8316	first	_
45-5	8317-8324	applied	_
45-6	8325-8336	generalized	_
45-7	8337-8343	linear	_
45-8	8344-8354	regression	_
45-9	8355-8356	(	_
45-10	8357-8360	GLM	_
45-11	8361-8362	)	_
45-12	8363-8368	model	_
45-13	8369-8371	to	_
45-14	8372-8380	identify	_
45-15	8381-8382	a	_
45-16	8383-8393	regression	_
45-17	8394-8398	line	_
45-18	8399-8402	for	_
45-19	8403-8406	the	_
45-20	8407-8419	relationship	_
45-21	8420-8427	between	_
45-22	8428-8435	imaging	_
45-23	8436-8447	modalitites	_
45-24	8448-8451	and	_
45-25	8452-8455	DOI	_
45-26	8456-8457	.	_

46-1	8458-8462	Then	_
46-2	8463-8466	the	_
46-3	8467-8472	slope	_
46-4	8473-8475	of	_
46-5	8476-8479	the	_
46-6	8480-8490	regression	_
46-7	8491-8495	line	_
46-8	8496-8499	was	_
46-9	8500-8503	the	_
46-10	8504-8517	corresponding	_
46-11	8518-8522	beta	_
46-12	8523-8528	value	_
46-13	8529-8531	of	_
46-14	8532-8535	the	_
46-15	8536-8543	loading	_
46-16	8544-8553	parameter	_
46-17	8554-8556	of	_
46-18	8557-8561	each	_
46-19	8562-8570	modality	_
46-20	8571-8572	(	_
46-21	8573-8576	kGM	_
46-22	8577-8580	for	_
46-23	8581-8584	the	_
46-24	8585-8587	GM	_
46-25	8588-8596	modality	_
46-26	8597-8600	and	_
46-27	8601-8604	kFC	_
46-28	8605-8608	for	_
46-29	8609-8612	the	_
46-30	8613-8615	FC	_
46-31	8616-8624	modality	_
46-32	8625-8626	)	_
46-33	8627-8628	.	_

47-1	8629-8630	Z	_
47-2	8631-8636	value	_
47-3	8637-8640	was	_
47-4	8641-8649	computed	_
47-5	8650-8652	as	_
47-6	8653-8656	the	_
47-7	8657-8667	difference	_
47-8	8668-8675	between	_
47-9	8676-8679	the	_
47-10	8680-8683	two	_
47-11	8684-8690	slopes	_
47-12	8691-8698	divided	_
47-13	8699-8701	by	_
47-14	8702-8705	the	_
47-15	8706-8714	standard	_
47-16	8715-8720	error	_
47-17	8721-8723	of	_
47-18	8724-8727	the	_
47-19	8728-8738	difference	_
47-20	8739-8746	between	_
47-21	8747-8750	the	_
47-22	8751-8757	slopes	_
47-23	8758-8759	.	_

48-1	8760-8762	As	_
48-2	8763-8766	the	_
48-3	8767-8770	GLM	_
48-4	8771-8776	model	_
48-5	8777-8781	gave	_
48-6	8782-8784	us	_
48-7	8785-8788	the	_
48-8	8789-8797	standard	_
48-9	8798-8803	error	_
48-10	8804-8806	of	_
48-11	8807-8811	each	_
48-12	8812-8817	slope	_
48-13	8818-8819	(	_
48-14	8820-8829	stand_kGM	_
48-15	8830-8833	for	_
48-16	8834-8837	the	_
48-17	8838-8840	GM	_
48-18	8841-8849	modality	_
48-19	8850-8853	and	_
48-20	8854-8863	stand_kFC	_
48-21	8864-8867	for	_
48-22	8868-8871	the	_
48-23	8872-8874	FC	_
48-24	8875-8883	modality	_
48-25	8884-8885	)	_
48-26	8886-8887	,	_
48-27	8888-8892	then	_
48-28	8893-8896	the	_
48-29	8897-8905	standard	_
48-30	8906-8911	error	_
48-31	8912-8914	of	_
48-32	8915-8918	the	_
48-33	8919-8929	difference	_
48-34	8930-8937	between	_
48-35	8938-8941	the	_
48-36	8942-8945	two	_
48-37	8946-8952	slopes	_
48-38	8953-8956	can	_
48-39	8957-8959	be	_
48-40	8960-8968	computed	_
48-41	8969-8971	as	_
48-42	8972-8973	.	_

49-1	8974-8978	Then	_
49-2	8979-8981	we	_
49-3	8982-8992	calculated	_
49-4	8993-8996	the	_
49-5	8997-8998	Z	_
49-6	8999-9004	value	_
49-7	9005-9007	as	_
49-8	9008-9010	Eq	_
49-9	9011-9012	.	_

50-1	9013-9014	(	_
50-2	9015-9016	1	_
50-3	9017-9018	)	_
50-4	9019-9020	:	_
50-5	9021-9031	Afterwards	_
50-6	9032-9033	,	_
50-7	9034-9036	we	_
50-8	9037-9045	computed	_
50-9	9046-9049	the	_
50-10	9050-9060	two-tailed	_
50-11	9061-9068	p-value	_
50-12	9069-9082	corresponding	_
50-13	9083-9085	to	_
50-14	9086-9089	the	_
50-15	9090-9091	Z	_
50-16	9092-9097	value	_
50-17	9098-9100	to	_
50-18	9101-9109	evaluate	_
50-19	9110-9113	the	_
50-20	9114-9126	significance	_
50-21	9127-9129	of	_
50-22	9130-9133	the	_
50-23	9134-9137	two	_
50-24	9138-9144	slopes	_
50-25	9145-9146	.	_

51-1	9147-9154	Genetic	_
51-2	9155-9162	pathway	_
51-3	9163-9171	analysis	_
51-4	9172-9177	After	_
51-5	9178-9188	converting	_
51-6	9189-9192	the	_
51-7	9193-9200	spatial	_
51-8	9201-9204	map	_
51-9	9205-9207	of	_
51-10	9208-9211	the	_
51-11	9212-9215	SNP	_
51-12	9216-9225	component	_
51-13	9226-9228	to	_
51-14	9229-9230	Z	_
51-15	9231-9237	scores	_
51-16	9238-9239	,	_
51-17	9240-9243	the	_
51-18	9244-9256	high-ranking	_
51-19	9257-9261	SNPs	_
51-20	9262-9263	(	_
51-21	9264-9267	|Z|	_
51-22	9268-9269	>	_
51-23	9270-9271	2	_
51-24	9272-9273	)	_
51-25	9274-9278	were	_
51-26	9279-9288	annotated	_
51-27	9289-9291	to	_
51-28	9292-9297	genes	_
51-29	9298-9299	.	_

52-1	9300-9302	To	_
52-2	9303-9310	further	_
52-3	9311-9320	interpret	_
52-4	9321-9324	the	_
52-5	9325-9337	relationship	_
52-6	9338-9345	between	_
52-7	9346-9349	the	_
52-8	9350-9353	SNP	_
52-9	9354-9363	component	_
52-10	9364-9367	and	_
52-11	9368-9381	schizophrenia	_
52-12	9382-9383	,	_
52-13	9384-9386	we	_
52-14	9387-9390	fed	_
52-15	9391-9396	these	_
52-16	9397-9400	top	_
52-17	9401-9413	contributing	_
52-18	9414-9419	genes	_
52-19	9420-9422	to	_
52-20	9423-9426	the	_
52-21	9427-9437	WebGestalt	_
52-22	9438-9446	software	_
52-23	9447-9450	for	_
52-24	9451-9455	Gene	_
52-25	9456-9464	Ontology	_
52-26	9465-9466	(	_
52-27	9467-9469	GO	_
52-28	9470-9471	)	_
52-29	9472-9480	analysis	_
52-30	9481-9482	,	_
52-31	9483-9488	which	_
52-32	9489-9493	used	_
52-33	9494-9495	a	_
52-34	9496-9511	hypergenometrix	_
52-35	9512-9516	test	_
52-36	9517-9519	to	_
52-37	9520-9526	detect	_
52-38	9527-9545	overrepresentation	_
52-39	9546-9548	of	_
52-40	9549-9552	the	_
52-41	9553-9558	genes	_
52-42	9559-9564	among	_
52-43	9565-9568	the	_
52-44	9569-9574	whole	_
52-45	9575-9581	genome	_
52-46	9582-9584	in	_
52-47	9585-9586	a	_
52-48	9587-9589	GO	_
52-49	9590-9598	category	_
52-50	9599-9600	.	_

